GlassScriptPhysician profile
Maryam Sickinger
NPI 1841514049
$6,506.64
in general payments reported to CMS, 2019-2025
29 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $166 · 2021: $818 · 2022: $1,037 · 2023: $757 · 2024: $1,508 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,179.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,621.78 | 2019-2025 | Aklief, Tri-Luma, Nemluvio |
| Biofrontera INC. | $803.92 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $537.93 | 2020-2025 | Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $437.91 | 2019-2022 | |
| Genzyme Corporation | $357.46 | 2021-2024 | |
| Dermavant Sciences, INC. | $305.95 | 2023-2024 | Vtama |
| Leo Pharma INC. | $297.94 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $230.98 | 2022 | |
| Epi Health, LLC | $229.86 | 2021 | |
| Ucb, INC. | $209.67 | 2023-2025 | Bimzelx, Cimzia, Zilbrysq |
| Lilly USA, LLC | $208.65 | 2021-2023 | Taltz |
| Regeneron Healthcare Solutions, INC. | $145.17 | 2025 | Libtayo |
| Abbott Laboratories | $133.84 | 2019 | |
| Botanix Sb INC | $129.11 | 2025 | Sofdra |
| Incyte Corporation | $127.16 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $120.86 | 2019-2022 | |
| Almirall LLC | $101.09 | 2019 | |
| Amgen INC. | $92.09 | 2020-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $90.61 | 2021 | |
| Maxx Orthopedics, INC. | $63.63 | 2019 | |
| Pacira Therapeutics, INC. | $49.45 | 2019-2021 | |
| Bioventus LLC | $47.38 | 2019-2025 | Xcell |
| Harmony Biosciences LLC | $40.85 | 2025 | |
| Abbvie INC. | $33.69 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $23.12 | 2023 | Exparel, Zilretta, Iovera |
| Merck Sharp & Dohme LLC | $18.71 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.58 | 2019 | |
| Orthogenrx INC. | $15.94 | 2020 | |
| Depuy Synthes Sales INC. | $15.31 | 2025 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Sickinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.